Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-016656
Filing Date
2025-04-30
Accepted
2025-04-30 16:14:53
Documents
22
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20045337x1_def14a.htm   iXBRL DEF 14A 1501881
5 GRAPHIC logo_rocketpharma.jpg GRAPHIC 36798
6 GRAPHIC ny20045337x1_pvp01.jpg GRAPHIC 147540
7 GRAPHIC ny20045337x1_pvp02.jpg GRAPHIC 97293
8 GRAPHIC ny20045337x1_pvp03.jpg GRAPHIC 141301
9 GRAPHIC ny20045337x1_pc01x1.jpg GRAPHIC 637651
10 GRAPHIC ny20045337x1_pc02x1.jpg GRAPHIC 671812
  Complete submission text file 0001140361-25-016656.txt   7031515

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA rckt-20250618.xsd EX-101.SCH 5146
3 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE rckt-20250618_lab.xml EX-101.LAB 17060
4 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE rckt-20250618_pre.xml EX-101.PRE 8573
25 EXTRACTED XBRL INSTANCE DOCUMENT ny20045337x1_def14a_htm.xml XML 325576
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36829 | Film No.: 25895399
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)